Great Promise For Addus Patients Who Can Benefit From Stem Cell therapy
Why This $2.00 Stem Cell Stock Will Help Addus Patients and why it will Become $100 per share.
Cesca therapeutics (KOOL) recently announced record shattering clinical trial results from their 17 patient CLI trial:
Before treatment, 100% of patients required amputation
12 months after treatment, 82.4% of patients had no amputation
Pain level before treatment on a scale of 0 to 10 was severe at 7.8
Pain level 12 months after treatment was almost non-existent at 0.2
6-minute walking distance before treatment was 14.5 meters
6-minute walking distance 12 months after treatment was 157meters
Before treatment, 11 patients had gangrene with or without ulceration
12 months after treatment 0 patients had gangrene or ulceration
NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
THERE WERE NO ADVERSE SIDE EFFECTS.
This same technology will be available for Addus cardiovascular and orthopedic patients.
Investors can buy Cesca at $20.00 in 12 months when more trial results are announced or investors can buy Cesca today at under $2.00.